FDA Warning Letters 94% In Concurrence With Chief Counsel At Six Months
This article was originally published in The Gray Sheet
Executive Summary
FDA warning and "untitled" letters are in sync with the Office of the Chief Counsel's interpretations a significant majority of the time, based on a six-month review of the policy that shifted warning letter authority from the field to the legal office
You may also be interested in...
Paper Tigers Or Paper Bullets? FDA Curbs Repeat Warning Letters, Violations
Enforcement policies under way within FDA's Office of the Chief Counsel could eliminate the practice of issuing multiple compliance warning letters, according to agency officials
Paper Tigers Or Paper Bullets? FDA Curbs Repeat Warning Letters, Violations
Enforcement policies under way within FDA's Office of the Chief Counsel could eliminate the practice of issuing multiple compliance warning letters, according to agency officials
FDA/CMS Device Trade Secret Memo Added To Regulatory Reform Wish List
FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform